Home

Baker Biotech Capital (GP), LLC

CIK 1244389 · last filed 2012-03-09

Baker Biotech Capital (GP), LLC is a corporate insider who has filed 42 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing shows the insider bought $407.2K of GHDX on Mar 9, 2012. Across all open-market trades the lifetime net is −$24.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $410.2M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$410.17M

Companies

10

Total Filings

42

Lifetime Open-Market Net

-$24.44M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
GENOMIC HEALTH INC (GHDX) Delisted Director 1,484,977 — — $8.49M 7 2012-03-09
VIROPHARMA INC (VPHM) Delisted 10%+ Owner 1,966,090 — — $8.89M 6 2011-12-16
AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted 10%+ Owner 912,719 — — -$5.86M 1 2011-08-03
INCY Director 3,485,752 $117.67 $410.17M $10.94M 7 2009-03-05
Ardea Biosciences, Inc./DE (RDEA) Delisted 10%+ Owner 1,646,964 — — $6.18M 2 2008-12-19
Aceragen, Inc. (IDRA) Delisted 10%+ Owner 12,301 $7.22 $88.9K -$1.02M 4 2008-09-30
NEUROGEN CORP (NRGN) Delisted Director — — — $0 1 2008-04-15
Seagen Inc. (SGEN) Delisted Director 3,933,090 $228.74 $899.66M -$50.86M 3 2008-03-14
ALLOS THERAPEUTICS INC (ALTH) Delisted 10%+ Owner 2,251,202 — — $2.10M 1 2008-01-09
Aceragen, Inc. (IDP) Delisted 10%+ Owner 521,466 — — -$3.30M 3 2007-12-04

Recent Filings

42 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2012-03-09 GENOMIC HEALTH INC (GHDX) Delisted Buy (P) +13,524 $407.2K EDGAR
2012-02-29 GENOMIC HEALTH INC (GHDX) Delisted Buy (P) +89,268 $2.59M EDGAR
2012-01-26 — Buy (P) +257,979 $4.67M
2011-12-16 VIROPHARMA INC (VPHM) Delisted Buy (P) +151,698 $4.14M EDGAR
2011-12-05 GENOMIC HEALTH INC (GHDX) Delisted Buy (P) +137,931 $3.82M EDGAR
2011-11-30 — Buy (P) +194,397 $2.72M
2011-11-17 GENOMIC HEALTH INC (GHDX) Delisted Buy (P) +1,374 $37.6K EDGAR
2011-11-07 GENOMIC HEALTH INC (GHDX) Delisted Buy (P) +360 $8.8K EDGAR
2011-10-06 VIROPHARMA INC (VPHM) Delisted Buy (P) +56,367 $1.02M EDGAR
2011-10-04 — Buy (P) +333,489 $3.88M
Showing 1–10 of 42
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.